Advances in molecular modeling of human cytochrome P450 polymorphism

Journal of Molecular Biology

Volumn 425, Issue 21, 2013, Pages 3978-3992

  Martiny, Virginie Y ^a,b   Miteva, Maria A ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

Author keywords

cytochrome P450; metabolizing enzymes; molecular modeling; polymorphism

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6;

ALLELE; BIOINFORMATICS; COMPUTER MODEL; DRUG RESPONSE; GENOTYPE; HUMAN; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; PROTEIN STRUCTURE; REVIEW;

3D; ADR; ADVERSE DRUG REACTIONS; CYTOCHROME P450; DDI; DRUG-DRUG INTERACTIONS; MD; METABOLIZING ENZYMES; MICRORNA; MIRNA; MOLECULAR DYNAMICS; MOLECULAR MODELING; NONSYNONYMOUS SINGLE NUCLEOTIDE POLYMORPHISM; NSSNP; PDB; PM; POLYMORPHISM; POOR METABOLIZER; PROTEIN DATA BANK; SINGLE NUCLEOTIDE POLYMORPHISM; SNP; THREE-DIMENSIONAL; ULTRARAPID METABOLIZER; UM;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; METABOLIC DETOXICATION, PHASE I; MODELS, MOLECULAR; POLYMORPHISM, GENETIC;

EID: 84885179307     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2013.07.010     Document Type: Review

References (145)

1. M. Ingelman-Sundberg The human genome project and novel aspects of cytochrome P450 research Toxicol Appl Pharmacol 207 2005 52 56
2. D. Singh, A. Kashyap, R.V. Pandey, and K.S. Saini Novel advances in cytochrome P450 research Drug Discov Today 16 2011 793 799
3. I. Johansson, and M. Ingelman-Sundberg Genetic polymorphism and toxicology - with emphasis on cytochrome p450 Toxicol Sci 120 2011 1 13
4. T. Shimada Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons Drug Metab Pharmacokinet 21 2006 257 276
5. C. Rodriguez-Antona, and M. Ingelman-Sundberg Cytochrome P450 pharmacogenetics and cancer Oncogene 25 2006 1679 1691
6. M. Ingelman-Sundberg Polymorphism of cytochrome P450 and xenobiotic toxicity Toxicology 181-182 2002 447 452
7. C. Bode The nasty surprise of a complex drug-drug interaction Drug Discov Today 15 2010 391 395
8. D. Morgan The importance of HT-ADME in drug discovery Bioanalysis 3 2011 2385 2387
9. H. Yin, J. Racha, S.Y. Li, N. Olejnik, H. Satoh, and D. Moore Automated high throughput human CYP isoform activity assay using SPE-LC/MS method: application in CYP inhibition evaluation Xenobiotica 30 2000 141 154
10. C.M. Masimirembwa, R. Thompson, and T.B. Andersson In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery Comb Chem High Throughput Screening 4 2001 245 263
11. I. Kariv, M.P. Fereshteh, and K.R. Oldenburg Development of a miniaturized 384-well high throughput screen for the detection of substrates of cytochrome P450 2D6 and 3A4 metabolism J Biomol Screening 6 2001 91 99
12. H. Sun, and D.O. Scott Structure-based drug metabolism predictions for drug design Chem Biol Drug Des 75 2010 3 17
13. G. Cruciani, E. Carosati, B. De Boeck, K. Ethirajulu, C. Mackie, and T. Howe MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist J Med Chem 48 2005 6970 6979
14. M.P. Gleeson, A. Hersey, and S. Hannongbua In-silico ADME models: a general assessment of their utility in drug discovery applications Curr Top Med Chem 11 2011 358 381
15. C. Merlot Computational toxicology - a tool for early safety evaluation Drug Discov Today 15 2010 16 22
16. G. Moroy, V.Y. Martiny, P. Vayer, B.O. Villoutreix, and M.A. Miteva Toward in silico structure-based ADMET prediction in drug discovery Drug Discov Today 17 2012 44 55
17. K.A. Phillips, D.L. Veenstra, E. Oren, J.K. Lee, and W. Sadee Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review JAMA 286 2001 2270 2279
18. S.N. Hart, and X.B. Zhong P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity Expert Opin Drug Metab Toxicol 4 2008 439 452
19. J. McGraw, and D. Waller Cytochrome P450 variations in different ethnic populations Expert Opin Drug Metab Toxicol 8 2012 371 382
20. S. Porcelli, C. Fabbri, E. Spina, A. Serretti, and D. De Ronchi Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism Expert Opin Drug Metab Toxicol 7 2011 1101 1115
21. N. Pinto, and M.E. Dolan Clinically relevant genetic variations in drug metabolizing enzymes Curr Drug Metab 12 2011 487 497
22. A. Ramamoorthy, and T.C. Skaar In silico identification of microRNAs predicted to regulate the drug metabolizing cytochrome P450 genes Drug Metab Lett 5 2011 126 131
23. A.D. Johnson, D. Wang, and W. Sadee Polymorphisms affecting gene regulation and mRNA processing: broad implications for pharmacogenetics Pharmacol Ther 106 2005 19 38
24. B. Yi, J.Y. Yang, and M. Yang Past and future applications of CYP450-genetic polymorphisms for biomonitoring of environmental toxicants J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 25 2007 353 377
25. M. Oscarson, R.A. McLellan, H. Gullsten, J.A. Agundez, J. Benitez, and A. Rautio Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism FEBS Lett 460 1999 321 327
26. A.R. Tricker Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour Toxicology 183 2003 151 173
27. S.M. Hoffman, P. Fernandez-Salguero, F.J. Gonzalez, and H.W. Mohrenweiser Organization and evolution of the cytochrome P450 CYP2A-2B-2F subfamily gene cluster on human chromosome 19 J Mol Evol 41 1995 894 900
28. M. Oscarson, H. Gullsten, A. Rautio, M.L. Bernal, B. Sinues, and M.L. Dahl Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase FEBS Lett 438 1998 201 205
29. H. Hadidi, K. Zahlsen, J.R. Idle, and S. Cholerton A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin Food Chem Toxicol 35 1997 903 907
30. N. Ariyoshi, Y. Sawamura, and T. Kamataki A novel single nucleotide polymorphism altering stability and activity of CYP2a6 Biochem Biophys Res Commun 281 2001 810 814
31. J.C. Mwenifumbo, N. Al Koudsi, M.K. Ho, Q. Zhou, E.B. Hoffmann, and E.M. Sellers Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent Hum Mutat 29 2008 679 688
32. K. Kitagawa, N. Kunugita, M. Kitagawa, and T. Kawamoto CYP2A66, a novel polymorphism in cytochrome p450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity J Biol Chem 276 2001 17830 17835
33. C. Xu, Y.S. Rao, B. Xu, E. Hoffmann, J. Jones, and E.M. Sellers An in vivo pilot study characterizing the new CYP2A67,8, and10 alleles Biochem Biophys Res Commun 290 2002 318 324
34. R. Yoshida, M. Nakajima, K. Nishimura, S. Tokudome, J.T. Kwon, and T. Yokoi Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A69) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro Clin Pharmacol Ther 74 2003 69 76
35. M. Haberl, B. Anwald, K. Klein, R. Weil, C. Fuss, and A. Gepdiremen Three haplotypes associated with CYP2A6 phenotypes in Caucasians Pharmacogenet Genomics 15 2005 609 624
36. S. Daigo, Y. Takahashi, M. Fujieda, N. Ariyoshi, H. Yamazaki, and W. Koizumi A novel mutant allele of the CYP2A6 gene (CYP2A611) found in a cancer patient who showed poor metabolic phenotype towards tegafur Pharmacogenetics 12 2002 299 306
37. M. Oscarson, R.A. McLellan, V. Asp, M. Ledesma, M.L. Bernal Ruiz, and B. Sinues Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A612) that causes reduced CYP2A6 activity Hum Mutat 20 2002 275 283
38. T. Fukami, M. Nakajima, R. Yoshida, Y. Tsuchiya, Y. Fujiki, and M. Katoh A novel polymorphism of human CYP2A6 gene CYP2A617 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo Clin Pharmacol Ther 76 2004 519 527
39. T. Fukami, M. Nakajima, E. Higashi, H. Yamanaka, H. Sakai, and H.L. McLeod Characterization of novel CYP2A6 polymorphic alleles (CYP2A618 and CYP2A619) that affect enzymatic activity Drug Metab Dispos 33 2005 1202 1210
40. M.K. Ho, J.C. Mwenifumbo, B. Zhao, E.M. Gillam, and R.F. Tyndale A novel CYP2A6 allele, CYP2A623, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent Pharmacogenet Genomics 18 2008 67 75
41. N. Al Koudsi, J.S. Ahluwalia, S.K. Lin, E.M. Sellers, and R.F. Tyndale A novel CYP2A6 allele (CYP2A635) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo Pharmacogenomics J 9 2009 274 282
42. K.A. Schoedel, E.B. Hoffmann, Y. Rao, E.M. Sellers, and R.F. Tyndale Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians Pharmacogenetics 14 2004 615 626
43. S.F. Zhou Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I Clin Pharmacokinet 48 2009 689 723
44. N.L. Benowitz, G.E. Swan, P. Jacob, C.N. Lessov-Schlaggar, and R.F. Tyndale CYP2A6 genotype and the metabolism and disposition kinetics of nicotine Clin Pharmacol Ther 80 2006 457 467
45. T. Kubota, C. Nakajima-Taniguchi, T. Fukuda, M. Funamoto, M. Maeda, and E. Tange CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation Pharmacogenomics J 6 2006 115 119
46. L. Gervot, B. Rochat, J.C. Gautier, F. Bohnenstengel, H. Kroemer, and V. de Berardinis Human CYP2B6: expression, inducibility and catalytic activities Pharmacogenetics 9 1999 295 306
47. D.M. Stresser, and D. Kupfer Monospecific antipeptide antibody to cytochrome P-450 2B6 Drug Metab Dispos 27 1999 517 525
48. T. Lang, K. Klein, T. Richter, A. Zibat, R. Kerb, and M. Eichelbaum Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles J Pharmacol Exp Ther 311 2004 34 43
49. K. Kreth, K. Kovar, M. Schwab, and U.M. Zanger Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs Biochem Pharmacol 59 2000 1563 1571
50. H. Yamazaki, K. Inoue, M. Hashimoto, and T. Shimada Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes Arch Toxicol 73 1999 65 70
51. E.L. Code, C.L. Crespi, B.W. Penman, F.J. Gonzalez, T.K. Chang, and D.J. Waxman Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation Drug Metab Dispos 25 1997 985 993
52. S.R. Faucette, H. Wang, G.A. Hamilton, S.L. Jolley, D. Gilbert, and C. Lindley Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers Drug Metab Dispos 32 2004 348 358
53. M. Hiratsuka, Y. Hinai, Y. Konno, H. Nozawa, S. Konno, and M. Mizugaki Three novel single nucleotide polymorphisms (SNPs) of the CYP2B6 gene in Japanese individuals Drug Metab Pharmacokinet 19 2004 155 158
54. T. Lang, K. Klein, J. Fischer, A.K. Nussler, P. Neuhaus, and U. Hofmann Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver Pharmacogenetics 11 2001 399 415
55. J. Zukunft, T. Lang, T. Richter, K.I. Hirsch-Ernst, A.K. Nussler, and K. Klein A natural CYP2B6 TATA box polymorphism (- 82T → C) leading to enhanced transcription and relocation of the transcriptional start site Mol Pharmacol 67 2005 1772 1782
56. V. Lamba, J. Lamba, K. Yasuda, S. Strom, J. Davila, and M.L. Hancock Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression J Pharmacol Exp Ther 307 2003 906 922
57. Y. Guo, P. Weller, E. Farrell, P. Cheung, B. Fitch, and D. Clark In silico pharmacogenetics of warfarin metabolism Nat Biotechnol 24 2006 531 536
58. K. Klein, T. Lang, T. Saussele, E. Barbosa-Sicard, W.H. Schunck, and M. Eichelbaum Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz Pharmacogenet Genomics 15 2005 861 873
59. M. Rotger, H. Tegude, S. Colombo, M. Cavassini, H. Furrer, and L. Decosterd Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals Clin Pharmacol Ther 81 2007 557 566
60. Z. Desta, T. Saussele, B. Ward, J. Blievernicht, L. Li, and K. Klein Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro Pharmacogenomics 8 2007 547 558
61. K. Tsuchiya, H. Gatanaga, N. Tachikawa, K. Teruya, Y. Kikuchi, and M. Yoshino Homozygous CYP2B66 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens Biochem Biophys Res Commun 319 2004 1322 1326
62. M. Rotger, S. Colombo, H. Furrer, G. Bleiber, T. Buclin, and B.L. Lee Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients Pharmacogenet Genomics 15 2005 1 5
63. D.W. Haas, H.J. Ribaudo, R.B. Kim, C. Tierney, G.R. Wilkinson, and R.M. Gulick Pharmacogenetics of efavirenz and central nervous system side effects: an adult AIDS clinical trials group study AIDS 18 2004 2391 2400
64. S.C. Gay, M.B. Shah, J.C. Talakad, K. Maekawa, A.G. Roberts, and P.R. Wilderman Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl)imidazole at 2.0-Å resolution Mol Pharmacol 77 2010 529 538
65. T. Hirota, S. Eguchi, and I. Ieiri Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs Drug Metab Pharmacokinet 28 2013 28 37
66. A.H. Wu Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance Clin Proteomics 8 2011 12
67. H. Yamazaki, and T. Shimada Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes Arch Biochem Biophys 346 1997 161 169
68. D. Seripa, A. Pilotto, F. Panza, and M.G. Matera Pharmacogenetics of cytochrome P450 (CYP) in the elderly Ageing Res Rev 9 2010 457 474
69. B.P. King, T.I. Khan, G.P. Aithal, F. Kamali, and A.K. Daly Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism Pharmacogenetics 14 2004 813 822
70. A.C. Allabi, J.L. Gala, and Y. Horsmans CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population Pharmacogenet Genomics 15 2005 779 786
71. J. Blaisdell, L.F. Jorge-Nebert, S. Coulter, S.S. Ferguson, S.J. Lee, and B. Chanas Discovery of new potentially defective alleles of human CYP2C9 Pharmacogenetics 14 2004 527 537
72. D. Si, Y. Guo, Y. Zhang, L. Yang, H. Zhou, and D. Zhong Identification of a novel variant CYP2C9 allele in Chinese Pharmacogenetics 14 2004 465 469
73. Y. Guo, Y. Zhang, Y. Wang, X. Chen, D. Si, and D. Zhong Role of CYP2C9 and its variants (CYP2C93 and CYP2C913) in the metabolism of lornoxicam in humans Drug Metab Dispos 33 2005 749 753
74. F. Zhao, C. Loke, S.C. Rankin, J.Y. Guo, H.S. Lee, and T.S. Wu Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose Clin Pharmacol Ther 76 2004 210 219
75. T.C. DeLozier, S.C. Lee, S.J. Coulter, B.C. Goh, and J.A. Goldstein Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians J Pharmacol Exp Ther 315 2005 1085 1090
76. K. Maekawa, H. Fukushima-Uesaka, M. Tohkin, R. Hasegawa, H. Kajio, and N. Kuzuya Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese Pharmacogenet Genomics 16 2006 497 514
77. T. Yin, K. Maekawa, K. Kamide, Y. Saito, H. Hanada, and K. Miyashita Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan Hypertens Res 31 2008 1549 1557
78. R.S. Kidd, T.B. Curry, S. Gallagher, T. Edeki, J. Blaisdell, and J.A. Goldstein Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin Pharmacogenetics 11 2001 803 808
79. J. van der Weide, L.S. Steijns, M.J. van Weelden, and K. de Haan The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement Pharmacogenetics 11 2001 287 291
80. R. Brandolese, M.G. Scordo, E. Spina, M. Gusella, and R. Padrini Severe phenytoin intoxication in a subject homozygous for CYP2C93 Clin Pharmacol Ther 70 2001 391 394
81. M.K. Higashi, D.L. Veenstra, L.M. Kondo, A.K. Wittkowsky, S.L. Srinouanprachanh, and F.M. Farin Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy JAMA 287 2002 1690 1698
82. R.S. Epstein, T.P. Moyer, R.E. Aubert, O.K. DJ, F. Xia, and R.R. Verbrugge Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study) J Am Coll Cardiol 55 2010 2804 2812
83. C. Moreau, F. Bajolle, V. Siguret, D. Lasne, J.L. Golmard, and C. Elie Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement Blood 119 2012 861 867
84. E. Sano, W. Li, H. Yuki, X. Liu, T. Furihata, and K. Kobayashi Mechanism of the decrease in catalytic activity of human cytochrome P450 2C9 polymorphic variants investigated by computational analysis J Comput Chem 31 2010 2746 2758
85. J.M. Lasker, M.R. Wester, E. Aramsombatdee, and J.L. Raucy Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations Arch Biochem Biophys 353 1998 16 28
86. J. Blaisdell, H. Mohrenweiser, J. Jackson, S. Ferguson, S. Coulter, and B. Chanas Identification and functional characterization of new potentially defective alleles of human CYP2C19 Pharmacogenetics 12 2002 703 711
87. S.C. Sim, C. Risinger, M.L. Dahl, E. Aklillu, M. Christensen, and L. Bertilsson A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants Clin Pharmacol Ther 79 2006 103 113
88. B.I. Drogemoller, G.E. Wright, D.J. Niehaus, L. Koen, S. Malan, and D.M. Da Silva Characterization of the genetic profile of CYP2C19 in two South African populations Pharmacogenomics 11 2010 1095 1103
89. P.M. Dansette, J. Rosi, G. Bertho, and D. Mansuy Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer Chem Res Toxicol 25 2012 348 356
90. D. Sibbing, D. Gebhard, W. Koch, S. Braun, J. Stegherr, and T. Morath Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy J Thromb Haemostasis 8 2010 1685 1693
91. U.M. Zanger, S. Raimundo, and M. Eichelbaum Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry Naunyn Schmiedebergs Arch Pharmacol 369 2004 23 37
92. S.C. Sim, and M. Ingelman-Sundberg The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects Hum Genomics 4 2010 278 281
93. T. Rau, G. Wohlleben, H. Wuttke, N. Thuerauf, J. Lunkenheimer, and M. Lanczik CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants - a pilot study Clin Pharmacol Ther 75 2004 386 393
94. P. Madadi, G. Koren, J. Cairns, D. Chitayat, A. Gaedigk, and J.S. Leeder Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine Can Fam Physician 53 2007 33 35
95. V.O. Dezentje, H.J. Guchelaar, J.W. Nortier, C.J. van de Velde, and H. Gelderblom Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer Clin Cancer Res 15 2009 15 21
96. V. Cojocaru, K. Balali-Mood, M.S. Sansom, and R.C. Wade Structure and dynamics of the membrane-bound cytochrome P450 2C9 PLoS Comput Biol 7 2011 e1002152
97. E.U. Griese, U.M. Zanger, U. Brudermanns, A. Gaedigk, G. Mikus, and K. Morike Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population Pharmacogenetics 8 1998 15 26
98. C. Sachse, J. Brockmoller, S. Bauer, and I. Roots Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences Am J Hum Genet 60 1997 284 295
99. T. Stuven, E.U. Griese, H.K. Kroemer, M. Eichelbaum, and U.M. Zanger Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction Pharmacogenetics 6 1996 417 421
100. F. Broly, D. Marez, N. Sabbagh, M. Legrand, S. Millecamps, and J.M. Lo Guidice An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis Pharmacogenetics 5 1995 373 384
101. J. de Leon, M.J. Arranz, and G. Ruano Pharmacogenetic testing in psychiatry: a review of features and clinical realities Clin Lab Med 28 2008 599 617
102. S.C. Sim, and M. Ingelman-Sundberg Update on allele nomenclature for human cytochromes P450 and the Human Cytochrome P450 Allele (CYP-allele) Nomenclature Database Methods Mol Biol 987 2013 251 259
103. S. Preissner, K. Kroll, M. Dunkel, C. Senger, G. Goldsobel, and D. Kuzman SuperCYP: a comprehensive database on cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions Nucleic Acids Res 38 2010 D237 D243
104. Z. Zhang, M.A. Miteva, L. Wang, and E. Alexov Analyzing effects of naturally occurring missense mutations Comput Math Methods Med 2012 2012 805827
105. Z. Zhang, S. Witham, M. Petukh, G. Moroy, M. Miteva, and Y. Ikeguchi A rational free energy-based approach to understanding and targeting disease-causing missense mutations J Am Med Inform Assoc 20 2013 643 651
106. A. Cavallo, and A.C. Martin Mapping SNPs to protein sequence and structure data Bioinformatics 21 2005 1443 1450
107. C.M. Dobson Protein folding and misfolding Nature 426 2003 884 890
108. P. Igaz, E. Pap, A. Patocs, A. Falus, Z. Tulassay, and K. Racz Genomics of steroid hormones: in silico analysis of nucleotide sequence variants (polymorphisms) of the enzymes involved in the biosynthesis and metabolism of steroid hormones J Steroid Biochem Mol Biol 82 2002 359 367
109. Y. Guo, P. Lu, E. Farrell, X. Zhang, P. Weller, and M. Monshouwer In silico and in vitro pharmacogenetic analysis in mice Proc Natl Acad Sci USA 104 2007 17735 17740
110. Q. Wei, L. Wang, Q. Wang, W.D. Kruger, and R.L. Dunbrack Testing computational prediction of missense mutation phenotypes: functional characterization of 204 mutations of human cystathionine beta synthase Proteins 78 2010 2058 2074
111. P. Yue, E. Melamud, and J. Moult SNPs3D: candidate gene and SNP selection for association studies BMC Bioinformatics 7 2006 166
112. P.C. Ng, and S. Henikoff SIFT: predicting amino acid changes that affect protein function Nucleic Acids Res 31 2003 3812 3814
113. I.A. Adzhubei, S. Schmidt, L. Peshkin, V.E. Ramensky, A. Gerasimova, and P. Bork A method and server for predicting damaging missense mutations Nat Methods 7 2010 248 249
114. L.L. Wang, Y. Li, and S.F. Zhou A bioinformatics approach for the phenotype prediction of nonsynonymous single nucleotide polymorphisms in human cytochromes P450 Drug Metab Dispos 37 2009 977 991
115. A. Eulalio, E. Huntzinger, and E. Izaurralde Getting to the root of miRNA-mediated gene silencing Cell 132 2008 9 14
116. N.R. Smalheiser EST analyses predict the existence of a population of chimeric microRNA precursor-mRNA transcripts expressed in normal human and mouse tissues Genome Biol 4 2003 403
117. S. Griffiths-Jones, R.J. Grocock, S. van Dongen, A. Bateman, and A.J. Enright miRBase: microRNA sequences, targets and gene nomenclature Nucleic Acids Res 34 2006 D140 D144
118. B. John, A.J. Enright, A. Aravin, T. Tuschl, C. Sander, and D.S. Marks Human microRNA targets PLoS Biol 2 2004 e363
119. B.P. Lewis, I.H. Shih, M.W. Jones-Rhoades, D.P. Bartel, and C.B. Burge Prediction of mammalian microRNA targets Cell 115 2003 787 798
120. M. Kertesz, N. Iovino, U. Unnerstall, U. Gaul, and E. Segal The role of site accessibility in microRNA target recognition Nat Genet 39 2007 1278 1284
121. M.J. de Groot, N.P. Vermeulen, J.D. Kramer, F.A. van Acker, and G.M. Donne-Op den Kelder A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108 Chem Res Toxicol 9 1996 1079 1091
122. S. Ekins, M.J. de Groot, and J.P. Jones Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites Drug Metab Dispos 29 2001 936 944
123. J.F. Wang, D.Q. Wei, L. Li, S.Y. Zheng, Y.X. Li, and K.C. Chou 3D structure modeling of cytochrome P450 2C19 and its implication for personalized drug design Biochem Biophys Res Commun 355 2007 513 519
124. F.C. Bernstein, T.F. Koetzle, G.J. Williams, E.F. Meyer, M.D. Brice, and J.R. Rodgers The Protein Data Bank: a computer-based archival file for macromolecular structures J Mol Biol 112 1977 535 542
125. A. Vedani, and M. Smiesko In silico toxicology in drug discovery - concepts based on three-dimensional models Altern Lab Anim 37 2009 477 496
126. F. Stoll, A.H. Goller, and A. Hillisch Utility of protein structures in overcoming ADMET-related issues of drug-like compounds Drug Discov Today 16 2011 530 538
127. J. Kirchmair, M.J. Williamson, J.D. Tyzack, L. Tan, P.J. Bond, and A. Bender Computational prediction of metabolism: sites, products, SAR, P450 enzyme dynamics, and mechanisms J Chem Inf Model 52 2012 617 648
128. E. Stjernschantz, and C. Oostenbrink Improved ligand-protein binding affinity predictions using multiple binding modes Biophys J 98 2010 2682 2691
129. J.D. Tyzack, M.J. Williamson, R. Torella, and R.C. Glen Prediction of cytochrome P450 xenobiotic metabolism: tethered docking and reactivity derived from ligand molecular orbital analysis J Chem Inf Model 53 2013 1294 1305
130. R.J. Unwalla, J.B. Cross, S. Salaniwal, A.D. Shilling, L. Leung, and J. Kao Using a homology model of cytochrome P450 2D6 to predict substrate site of metabolism J Comput Aided Mol Des 24 2010 237 256
131. G. Rossato, B. Ernst, M. Smiesko, M. Spreafico, and A. Vedani Probing small-molecule binding to cytochrome P450 2D6 and 2C9: an in silico protocol for generating toxicity alerts ChemMedChem 5 2010 2088 2101
132. C. Minutolo, A.D. Nadra, C. Fernandez, M. Taboas, N. Buzzalino, and B. Casali Structure-based analysis of five novel disease-causing mutations in 21-hydroxylase-deficient patients PLoS One 6 2011 e15899
133. S. Teng, T. Madej, A. Panchenko, and E. Alexov Modeling effects of human single nucleotide polymorphisms on protein-protein interactions Biophys J 96 2009 2178 2188
134. O. Sperandio, B.O. Villoutreix, and M.A. Miteva Structure-based virtual screening M.A. Miteva, In silico lead discovery 2011 20 46
135. N. Moitessier, P. Englebienne, D. Lee, J. Lawandi, and C.R. Corbeil Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go Br J Pharmacol 153 2008 S7 S26
136. E. Yuriev, and P.A. Ramsland Latest developments in molecular docking J Mol Recognit 26 2013 215 239
137. X.Y. Meng, H.X. Zhang, M. Mezei, and M. Cui Molecular docking: a powerful approach for structure-based drug discovery Curr Comput Aided Drug Des 7 2011 146 157
138. C.R. Satyanarayana, A. Devendran, M. Jayaraman, J. Mannu, P.P. Mathur, and S.D. Gopal Influence of the genetic polymorphisms in the 5′ flanking and exonic regions of CYP2C19 on proguanil oxidation Drug Metab Pharmacokinet 24 2009 537 548
139. S.J. Teague Implications of protein flexibility for drug discovery Nat Rev Drug Discov 2 2003 527 541
140. S. Cong, X.T. Ma, Y.X. Li, and J.F. Wang Structural basis for the mutation-induced dysfunction of human CYP2J2: a computational study J Chem Inf Model 53 2013 1350 1357
141. L.M. King, J. Ma, S. Srettabunjong, J. Graves, J.A. Bradbury, and L. Li Cloning of CYP2J2 gene and identification of functional polymorphisms Mol Pharmacol 61 2002 840 852
142. M. Spiecker, H. Darius, T. Hankeln, M. Soufi, A.M. Sattler, and J.R. Schaefer Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2 Circulation 110 2004 2132 2136
143. S.S. Lee, H.E. Jeong, K.H. Liu, J.Y. Ryu, T. Moon, and C.N. Yoon Identification and functional characterization of novel CYP2J2 variants: G312R variant causes loss of enzyme catalytic activity Pharmacogenet Genomics 15 2005 105 113
144. H. Fukunishi, H. Yagi, K. Kamijo, and J. Shimada Role of a mutated residue at the entrance of the substrate access channel in cytochrome p450 engineered for vitamin D(3) hydroxylation activity Biochemistry 50 2011 8302 8310
145. H. Zhang, C. Kenaan, D. Hamdane, G.H. Hoa, and P.F. Hollenberg Effect of conformational dynamics on substrate recognition and specificity as probed by the introduction of a de novo disulfide bond into cytochrome P450 2B1 J Biol Chem 284 2009 25678 25686